Pfiz­er takes its op­tion in An­Tol­Rx deal; Se­cu­ra Bio scores ac­cess to $145M for can­cer drug launch­es

→ Two-and-a-half years af­ter Pfiz­er stepped up to seed the biotech start­up An­Tol­Rx, the phar­ma gi­ant has stepped in to take their op­tion on an im­mune tol­er­ance ther­a­py for Type 1 di­a­betes. Based on the lab work of Fran­cis­co Quin­tana, a pro­fes­sor of neu­rol­o­gy at Brigham and Women’s Hos­pi­tal in Boston — who’s spe­cial­ized in anti­gen-spe­cif­ic tol­er­ance — An­Tol­Rx has been work­ing on a pipeline of im­mune tol­er­ance ther­a­pies for au­toim­mune and in­flam­ma­to­ry ail­ments. The biotech is pick­ing up an un­spec­i­fied up­front pay­ment in the deal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.